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Skin-draining LN contain several phenotypically distinguishable DC populations, which
may be immature or mature. Mature DC are generally considered to have lost the
capacity to acquire and present newly encountered Ag. Using antibody-opsonized
liposomes as Ag carriers, we show that mature DC purified from skin explants are able to
efficiently capture liposomes, process Ag encapsulated within them and activate Ag-
specific CD4+ T cells. Explant DC from mice with Langerhans cells (LC) expressing the
primate diphtheria toxin receptor that were exposed to diphtheria toxin in vivo
presented Ag as well as explant DC from wild-type mice, indicating that LC are not
required and dermal DC are probably responsible for this presentation. We further show
that all DC subtypes from LN that capture opsonized Ag are capable of cross-presenting
it to CD8+ T cells. Induction of additional maturation in vivo by LPS or treatment with
double-stranded RNA did not alter the Ag presentation capacity of the skin or LN DC
subtypes. These results suggest that mature DC present in skin-draining LN may play an
important role in the induction of primary and/or secondary immune responses against
Ag delivered to the LN that they take up by receptor-mediated endocytosis.
Introduction
Dendritic cells (DC) capture, process and present Ag to
T cells. Several phenotypically distinct DC populations
have been described in mouse lymphoid organs,
including LN draining the skin [1]. We have an
incomplete understanding of possible differences in
function of DC that this heterogeneity implies. In
addition to differences in expression of markers
(CD11c, CD8a, CD205) used to define DC subsets,
another level of heterogeneity exists with respect to the
levels of MHC and costimulatory molecules expressed,
correlating with their maturation. DC in the periphery,
comprising dermal DC as well as Langerhans cells (LC)
in the skin, take up Ag, undergomaturation (particularly
following microbial contact) and migrate via afferent
lymphatic vessels into the T cell areas of draining LN.
Other DC present in LN or spleen either come from the
blood or are derived from precursors already located in
those organs [2]. Under steady-state conditions in the
mouse, the latter DC populations have a predominately
immature phenotype [3]. Thus, immature and mature
DC coexist in lymphoid tissue.
Antigen processing
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It is thought that tolerance to self Ag is maintained by
its presentation by immature DC, whereas DC matura-
tion subsequent to contact with Ag, especially in
association with agents activating Toll-like receptors,
is required for presentation of exogenous Ag. DC
maturation is correlated with the reduction of intra-
cellular stores of MHC class II molecules and their
increased expression at the cell surface. According to
this hypothesis, DC maturation is irreversible, and Ag
uptake is down-regulated as the ability to present Ag is
up-regulated [4]. This is part of a process enabling the
immune system to focus attention on the Ag that
activates it, called antigenic memory [3]. This hypoth-
esis is based on demonstrations that mature DC have a
reduced capacity to take up and present soluble Ag in the
context of class II [3, 5]. Nevertheless, acquisition of
soluble Ag was reported to be affected by maturation
induced by exposure toToll-receptor ligands such as LPS
in vitro but not in vivo [6].
In addition, maturation has been reported to result in
reduced presentation of exogenous Ag by DC toTcells in
the context of class I, called cross-presentation. Inhibi-
tion of cross-presentation did not affect the capacity to
present endogenous Ag associated with class I but
appeared to be related to a reduced ability to
phagocytose Ag [7]. Indeed, maturation of LC [8] and
splenic DC [7] has been shown to reduce their capacity
to acquire particulate Ag.
We have studied Ag delivery to DC using liposomes as
Ag carriers. Liposomes may be made with amounts of
encapsulated Ag that are limited only by liposome size
and Ag solubility. Despite the relatively poor uptake of
“naked” liposomes by DC in vitro, they may be targeted
to cell surface molecules expressed by DC, including the
immunoglobulin Fc receptor (FcR), permitting them to
deliver Ag into DC and resulting in presentation of
quantities of Ag orders of magnitude lower than the
same Ag in free form. CD4+ T cells may be efficiently
stimulated by class II-associated Ag in opsonized
liposomes presented by bone-marrow DC that are
relatively immature [9]. In contrast, class I-associated
Ag presentation by DC is developmentally regulated [10,
11], and acquisition and presentation of the same Ag
within FcR-targeted liposomes to CD8+ T cells required
more mature DC [10]. This implies that partial DC
maturation is not an obstacle per se to Ag uptake and
presentation, provided that a means exists for assuring
the binding and endocytosis of the liposomes. These
results were confirmed by another group for partially
mature bone marrow-derived DC presenting soluble
immune complexes, though fully mature bone marrow
DC were reported to down-regulate endocytosis and
cross-presentation of soluble immune complexes [12].
In this paper we have evaluated the capacity of DC
obtained from LN and skin to present liposome-
encapsulated Ag both in vitro and in vivo. We determined
that the most mature DC populations retain the capacity
to capture opsonized liposomes and to present the Ag
encapsulated within them to both Ag-specific CD4+ and
CD8+ T cells.
Results
At least six DC subtypes in skin-draining LN
CD11c+ skin-draining LN DC are heterogeneous. Six
subtypes may be distinguished by flow cytometry. As
shown in Fig. 1A, among these are the CD8a+CD205+
subtype (referred to as CD8a+); the CD8a–CD205–
subtype (referred to as CD8a–), which contains both
CD4– and CD4+ DC (Fig. 1B); the CD8alowCD205int
population, which corresponds to dermal DC; and the
CD8alowCD205high population that are the LC [1].
Among the subtypes delineated with CD8a and
CD205 markers, only the CD8a+CD205– subtype was
PDCA-1+, B220+, Ly6G/C+ and CD4+ (Fig. 1B),
indicating that those cells are plasmacytoid DC (pDC).
The CD8a+CD205– population was not observed in a
previous report [1] using CD8a and CD205 staining,
presumably because this study used a depletion protocol
including anti-B220 Ab, so that pDC were eliminated.
Figure 1. FACSJ profiles of skin-draining LN DC. (A) DC purified
from LN were stained with mAb to CD11c, CD205 and CD8a.
The dot plot indicates CD11c+ gated cells. In this and
subsequent FACSJ profiles, a log scale of 100–104 was used.
(B) The different DC subtypes were stained with mAb to
PDCA-1, B220, Ly6G/C and CD4 and evaluated by flow
cytometry.
Eur. J. Immunol. 2007. 37: 1184–1193 Antigen processing 1185
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
The role of these different LN DC subtypes in the
immune response is poorly understood, and the
necessity for such DC heterogeneity needs to be
clarified. We studied the Ag presentation capacity of
these DC in a model where the Ag is targeted to an
endocytosed receptor.
Targeting of liposome-encapsulated Ag to the
FccRI receptor of DC
OVA-containing liposomes, 100 nm in diameter, were
made with a fraction of DNP-bearing phospholipids in
their membranes. Consequently, they may be opsonized
with anti-DNP Ab and bind to and are endocytosed by
DC through their Fcc receptors (FccR) [9, 10, 13]. Using
an IgG2a Ab, which targets principally FccRI (CD64)
and the newly described FccRIV [14], we showed that
four LN DC subtypes (CD8a+, CD8a–, dermal and LC)
were able to capture the liposomes (Fig. 2). In contrast,
pDC were practically unable to capture opsonized
liposomes (Fig. 2) and were not further analyzed for
Ag presentation in the current study. As dermal DC and
LC obtained from LN have migrated there from the skin,
we also analyzed liposome binding of skin-derived DC
directly. To do so, ear explants were incubated overnight
with 6Ckine (CCL21) [1], and the cells that crawled out
of the explants were collected and characterized as DC
by CD11c expression. Explant-derived DC showed high
liposome binding in the presence of FcR targeting,
whereas they did not bind the liposomes in the absence
of anti-DNP Ab (Fig. 2).
Maturation status of skin explant and LN DC
subpopulations
The four LN DC subtypes evaluated have different
origins, with the CD8a+ and CD8a– DC coming from the
blood, the dermal DCmigrating from the dermis and the
LC migrating from the epidermis [1]. They differ also in
their levels of expression of coactivation markers and
MHC molecules (Fig. 3). The CD8a+ and CD8a–
populations have an immature phenotype, with hetero-
geneous expression of MHC class II molecules and low
expression of CD80, CD86 and CD40, whereas the
dermal DC and the LC have a mature phenotype, with
higher levels of CD40, CD80 and CD86 and high levels of
MHC class II. As reported in an earlier study [1], skin
explant DC show amature phenotype, with high levels of
surface MHC class II. We also studied surface markers of
LN DC subtypes purified from mice that were treated
with LPS by intravenous injection 14 h previously. This
treatment is known to induce DC maturation and up-
regulation of costimulatory markers [15, 16]. As shown
in Fig. 3, LPS injection induced up-regulation of CD80,
CD86 andMHC class II expression by the most immature
Figure 2. Liposome binding by LN DC populations. DC purified
from LN and skin explants were stained with Ab to CD11c,
CD205 and CD8a to define the different DC subtypes. These
were incubatedwith carboxyfluorescein-containing liposomes
without (untargeted) or with (FcR-targeted) IgG2a anti-DNPAb
(U7.27.7). Fluorescence was then analyzed by flow cytometry.
Figure 3. Maturation status of LN DC. DC purified from LN or
skin of normal mice or mice injected with 3 lg LPS intra-
venously 14 h previously were stained with mAb to CD11c,
CD205 and CD8a to define the different DC subtypes and also
with Ab to CD40, CD80, CD86 or MHC class II and evaluated by
flow cytometry.
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LN DC, the CD8a– and CD8a+ subtypes (the mean
fluorescence intensity of MHC II more than doubled),
whereas on dermal DC there was a slight increase in
CD80 and CD86 expression but no increase in CD40 and
MHC class II expression. LPS treatment had no effect on
LC isolated from LN (Fig. 3) or MHC class II levels on
explant DC (data not shown). Moreover, in our hands
there were no major differences when LPS was injected
intravenously, as in the data presented in Fig. 3, or
subcutaneously or intradermally (data not shown). The
latter route of LPS administrationwas used by Ruedl [6].
Efficiency of mature DC in presenting Ag to CD4+
TCR-transgenic T cells after FcR targeting
We next investigated Ag presentation to naive T cells by
LN DC populations. The different DC subtypes were
sorted and incubated with peptide, free Ag or liposome-
encapsulated Ag and then washed, followed by addition
of CD4+ T cells (OT-II). We did not observe any
differences in the proliferation rates of OT-II cells by
CFSE dilution 3 days after their stimulation with the
peptide OVA323–339 presented by the different DC
subtypes (Fig. 4A). This peptide can load membrane
MHC class II molecules directly. At the lowest concen-
tration of Ag used in the experiment (1 nM), liposomes
added in the absence of opsonizing Ab did not induce
any proliferation of the OT-II cells (Fig. 4A). In some
cases, some proliferation occurred when liposomes
containing 10 nM Ag were added (Fig. 4B), depending
on the DC subtype (see below). When liposomes were
targeted to the FcR, we observed strong CD4+ T cell
proliferation, with the highest rate of proliferation
obtained with the most mature DC, the dermal DC in
particular and also the LC isolated from LN (Fig. 4A).
Opsonized liposomes made without encapsulated OVA
did not induce any proliferation (data not shown). Thus,
these DC populations efficiently took up opsonized
liposomes, and the encapsulated OVA was efficiently
processed and presented in the context of class II.
The Ag presentation capacity of ear skin explant-
derived DC was then tested. As shown in Fig. 4B (left
panel), a higher number of OT-II cells recovered from
cultures with explant-derived DC proliferated than in
cultures with LN-derived DC. Explant DC had the
capacity to process and present Ag to these CD4+ T cells
Figure 4. Proliferation of CD4+ TCR-transgenic T cells in response to Ag-loaded DC subtypes. (A) DC populations (20 000/well) were
pulsed overnight with 1 lM OVA peptide OVA323–339 or with OVA-containing liposomes (1 nM =0.043 lg/mL) without (untargeted)
or with (FcR-targeted) IgG2a anti-DNP Ab. The cells were washed, and CFSE-stained OT-II cells were added for 72 h. OT-II
proliferation was measured by CFSE intensity decrease. Data are representative of at least four experiments. (B) LN DC subtypes
(3000/well) and explant DC isolated from control mice ormice injectedwith LPS 14 h previously were pulsed for 6 h with different
concentrations of free OVA (lM scale) or OVA-containing liposomes (nM scale) without (untargeted) or with (FcR-targeted) IgG2a
anti-DNP Ab. After washing, 20 000 CFSE-labeled OT-II cells were added, and after 72 h CFSElow cells were counted by flow
cytometry. Data are representative of three experiments.
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not only when the Ag (10 nM) was endocytosed through
the FCR but alsowhen free Agwas provided at 100-times
higher concentration (1 lM) (Fig. 4B). Moreover, with
the highest concentration of Ag (10 nM) in liposomes,
explant-derived DC induced some OT-II proliferation
without FcR endocytosis, showing that these skin-
derived DC maintained their endocytic potential.
As we were surprised by the strong Ag presentation
capacity of mature DC isolated from LN and skin, we
studied the Ag presenting capacity of DC subtypes
purified from mice 10 h following intravenous injection
of LPS. As shown in Fig. 4B (right panel), we did not
observe marked modification of the Ag presentation
capacity of the different DC subtypes to OT-II cells,
suggesting that even after LPS-induced maturation, LN
DC as well as explant DC can still process and efficiently
present Ag internalized by receptor-mediated endo-
cytosis by the FcR as well as free Ag at higher
concentrations.
The results in Fig. 4A and B were obtained after 6 or
more hours of incubation of the Ag with the DC before
washing and adding T cells, but if this time was reduced
to 45 min, LN-isolated dermal DC still presented Ag to
CD4+ T cells better than the other LN DC (data not
shown). DC isolation from skin explants required CCL21
treatment, which is reported to increase their capacity
for receptor-mediated endocytosis [17] and their
immunogenicity [18]. Consequently, we tested the
effect of CCL21 on Ag presentation by LN DC. The
treatment of LN DC (Fig. 5) or bone marrow-derived DC
(data not shown) overnight with CCL21 had no effect on
their capacity to stimulate T cells.
Explant-derived DC are a mixture of dermal DC and
LC. We studied the Ag presentation capacity of explants
depleted of LC to evaluate the Ag acquisition and
presentation capacities of explant dermal DC as a pure
population. We used knock-in mice expressing the
primate diphtheria toxin receptor (DTR) under the
control of the langerin promoter; the homologous
receptor in WT mice does not bind diphtheria toxin
(DT). Injection of DT induces the specific and complete
depletion of LC in the skin and in LN of knock-in mice
whose LC express the DTR (LangDTR mice) [19]. We
collected ear skin explant DC from LangDTR and WT
mice in medium containing CCL21 2 days after DT
injection. The cells collected from the explants of
LangDTR mice were dermal DC, confirming published
results [19]. The Ag presentation activity of these cells
was unchanged relative to explants from WT mice
(Fig. 6). Consequently, we could find neither enhanced
nor diminished activity for the tested responses of
dermal DC in the absence of LC, despite the fact that LC
purified from LN appeared to be perfectly adequate for
Ag presentation to CD4+ and CD8+ Tcells (Fig. 5 and 6).
Figure 5. Proliferation of CD4+ TCR-transgenic T cells in
response to chemokine-treated DC subtypes. Same as in
Fig. 4 with LN DC incubated (or not) overnight with CCL21 to
mimic the treatment used to obtain explant DC. Data are
representative of two experiments.
Figure 6. CD4+ and CD8+ T cell proliferation in response to
explant DC devoid of LC. Explant DCwere obtained fromWTor
LangDTRmice treatedwith DT. DCwere incubatedwith Ag and
then T cells as previously described and proliferation assessed
for CD4+ T cells (A) and CD8+ T cells (B). Data are representative
of two experiments.
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CD4+ T cell help for CD8+ T cell activation by LN
DC after FcR targeting
We evaluated the capacity of the different DC subtypes
to cross-present Ag to CD8+ T cells. In the absence of
targeting of liposomes to the FcR, the different DC
subtypes did not induce CD8+ Tcell proliferation, but all
DC populations cross-presented the Ag and stimulated
OT-I proliferation when incubated with FcR-targeted
liposomes (Fig. 7A). This proliferation either depended
on (CD8a– and CD8a+ DC, LC) or was enhanced by
(dermal DC) co-culture with OT-II cells. As for the
induction of CD4+ T cell proliferation, absence of LC in
the explant DC population (using DT-treated LangDTR
mice) did not markedly modify the induction of CD8+
T cell proliferation (Fig. 6B).
CD8+ T cell activation was confirmed with a
cytotoxicity assay (Fig. 7B). All DC subpopulations
induced cytotoxic CD8+ Tcells. The four LN DC subtypes
incubated with the MHC class I-restricted OVA257–264
(SIINFEKL) peptide induced cytotoxicity of OT-I T cells
to the same extent, regardless of whether OT-II cells
were present. In experiments using FcR-targeted lipo-
somes, all LN DC subtypes were able to induce cytotoxic
CD8+ T cells with the help of Ag-specific CD4+ T cells.
The highest lysis was obtained with LN dermal DC and
explant DC.
No marked effect of LPS or poly I:C on
presentation of liposome-encapsulated Ag in vivo
In vivo injection of LPS induced maturation of DC and
abrogated cross-presentation of viral Ag [7]. As we did
not observe this effect on the function of DC derived
from such mice in vitro, we addressed the question in
vivo using our liposome-based model. DC take up
liposomes following subcutaneous or intradermal injec-
tion, and the processed Ag is presented in the draining
LN. The injection of Ag encapsulated in liposomes
similar to those used here induced strong CD4+ and
CD8+ T cell primary as well as memory responses [20].
We thus compared the proliferation rates of adoptively
transferred CFSE-labeled CD8+ T cells (OT-I) in the
draining LN of mice that were previously treated or not
with LPS or poly I:C intravenously and then immunized
by intradermal injection in the ear. These mice also
received unlabeled OT-II cells, so that CD4+ T cell help
was not limiting [20]. Liposomes induced strong
proliferation of adoptively transferred Ag-specific
CD8+ T cells in draining LN. No proliferation was
observed in the non-draining LN (Fig. 8). The
proliferation rate was slightly reduced when mice
received LPS but was not modified when mice received
poly I:C. From these experiments we can conclude that
the capacity of DC for presentation of liposome-
Figure 7. CD8+ T cell proliferation and cytotoxicity in response to OVA-containing liposomes. (A) DC populations (3000 cells) were
incubated in the presence of CFSE-labeled OT-I cells, with or without OT-II cells overnight, without Ag or with 10 nM OVA-
containing liposomes, without (untargeted) or with (FcR-targeted) IgG2a anti-DNP Ab. The numbers of CFSElow OT-I cells
corresponding to the gates established for OT-II cells in Fig. 4 are presented as bar graphs. (B) DC populations (3000 cells, in
duplicates) were incubated overnight without Ag, with SIINFEKL peptide (10 nM) or with OVA-containing liposomes (10 nM,
untargeted or FcR-targeted). After washing, 20 000 OT-I cellswere added, with or without 10 000 OT-II cells. After 5 days, SIINFEKL
peptide-loaded 51Cr-labeled RMA targets were added to the cultures and lysis measured after 4 h. Data are representative of at
least four experiments.
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encapsulated Ag is undiminished, even in LPS- or poly
I:C-treated mice.
Discussion
Mature DC are generally considered to be efficient in the
presentation of Ag but not its acquisition [4]. Results in
this paper show that DC subtypes isolated from skin
(explant DC), skin-derived DC (LC and dermal DC) as
well as non-skin-derived CD8a– and CD8a+ DC in
draining LN efficiently presented OVA encapsulated in
Ab-opsonized liposomes to Ag-specific CD4+ T cells and
cross-presented the same Ag to CD8+ Tcells. The activity
of DC was unaffected by induction of increased maturity
by exposure of these cells in vivo to LPS or poly I:C prior
to Ag contact.
As they have increased expression of costimulatory
molecules, mature DC would be expected to be optimal
for stimulation of T cell responses if they retain the
capacity to internalize and present Ag. These considera-
tions may be relevant for the role of receptor-mediated
endocytosis in acquisition of microorganisms or of Ag
derived from them in vivo. In particular, FccRI and
FccRIII expressed by DC in C57BL/6 mice have recently
been shown to be important receptors for induction of
Th1 and cytotoxic responses to infection by Leishmania
major following the opsonization of amastigotes by Ab
produced early in the infection or by passively opsonized
L. major promastigotes [21]. It is also known that anti-
Leishmania responses are initiated by LN-resident DC
[22]. Thus, mature and/or immature DC in LN could
internalize IgG-opsonized amastigotes or L. major Ag
delivered to LN, and this Ag uptake and processing could
be responsible for the acquisition of protective im-
munity. Infection by Leishmania causes an inflammatory
response inducing DC maturation, but it is not known at
what stage of their development DC acquire Ag via
the FcR.
Most of the literature on the down-regulation of Ag
acquisition by mature DC relates to uptake of large
particles [8] or of fluid-phase markers in vitro (reviewed
in [23]), whereas receptor-mediated endocytosis was
less affected by DCmaturation in vitro [23, 24] or in vivo
[6]. The 100-nm liposomes used in this study are at the
size limit for efficient uptake by receptor-mediated
endocytosis via the FcR [23]. FcR-mediated uptake of Ag
[10, 13, 25] activates DC by a Syk-dependent pathway
independent of Toll-like receptors and permits their
presentation of Ag in the context of class I [26]. Other
receptors certainly participate in liposome uptake in
vivo. Liposomes incubated with serum bind numerous
proteins [27], of which an unknown number may
promote cell binding and activate DC. Indeed, while it is
an excellent receptor for liposomes in these studies, the
DC FcR is not an obligatory target in vivo, since Ag in
liposomes was efficiently presented in mice unable to
make Ab [20].
Despite their relatively small size, liposomes may
become opsonized with numerous ligands, increasing
their avidity for cell surface receptors. This property, in
conjunction with their large Ag-carrying capacity,
presumably accounts for the advantage of liposomes
for uptake and presentation by mature DC as compared
to immune complexes [12, 25]. Although concomitant
exposure of DC to Ag and double-stranded RNA
stimulated cross-presentation [7, 28], it has been
reported that pretreatment of mice with TLR ligands
inhibited presentation of Ag from viruses injected
intravenously or applied to abraded skin [7]. Such
impaired responses were not observed when we injected
liposomes into mice previously treated with LPS or
poly I:C.
The question of which DC populations are capable of
cross-presentation of Ag has been a subject of debate.
Figure 8. CD8+ T cell proliferation in vivo. CFSE-labeled OT-I
(2  106) and OT-II (2  106) cells were injected intravenously
into C57BL/6 mice. After 3 days, mice were treated intra-
venously with PBS, LPS (3 lg) or poly I:C (50 lg). Mice were
immunized 10 h later intradermally in one ear with liposome-
encapsulated Ag (3 lg). Proliferation was assessed after 4 days
by analyzingCFSE levels inOT-I cells in LNdraining the injected
and non-injected ears. Data are representative of two experi-
ments.
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Only the CD8a+ DC subtype was reported to be capable
of cross-presentation in response to free Ag in vivo or in
vitro [29]. The same cell population was uniquely
capable of cross-tolerizing CD8+ T cells [30]. Never-
theless, when Ag was injected in immune complexes,
CD8a– DC from the spleen had the same cross-
presentation capacity as CD8a+ DC [31]. In the present
paper, we confirm the latter study that was performed
using immature splenic DC and also demonstrate that all
LN DC subtypes are capable of cross-presentation in
response to FcR-targeted liposomes. Thus, DC popula-
tions relevant to T cell stimulation in vivo may acquire
and present opsonized Ag in a manner similar to bone
marrow-derived DC [9, 10, 25] and DC lines [25].
Since in the present study, DC populations were
extensively purified, Ag was taken up by the cells that
presented it directly toTcells, or Ag was transferred into
DC of the same type that presented it. Nevertheless, this
does not preclude transfer of Ag in vivo from skin-
draining DC to LN resident DC, as suggested previously
[32], and the recipient population may include mature
DC.
Materials and methods
Mice
Female 6- to 8-wk-old C57BL/6 mice were purchased from
Charles River. Rag–/– OT-I and OT-II mice were purchased from
Jackson Immunoresearch. LangDTR-EGFP mice were devel-
oped and maintained at the CIML and described previously
[19]. Animals were treated according to national and
institutional guidelines. OT-I mice have CD8+ Tcells transgenic
for a TCR specific for the chicken ovalbumin (OVA) SIINFEKL
(OVA257–264) peptide in the context of H-2K
b [33]. OT-II mice
have CD4+ T cells transgenic for a TCR specific for the
OVA323–339 peptide in the context of H-2IA
b [34].
Antibodies
U7.27.7, an IgG2a anti-DNP mAb, was provided by Z. Eshhar
(Weizmann Institute, Rehovot, Israel). Ab specific for CD4,
CD11c, CD8a, CD40, CD80, CD86, CD16/32, Ly6G/C (GR-1,
RB6–85C) [35], MHC class I and MHC class II were purchased
from BD Pharmingen (San Diego, CA). The anti-CD205 mAb
was purchased from Cedarlane. The pDC-specific mAb PCDA-1
was purchased from Miltenyi Biotec.
Liposomes
Liposomes were made from 65% mol/mol dimyristoyl
phosphatidylcholine, 34.5% cholesterol (Sigma-Aldrich, St.
Louis, MO) and 0.5% DNP-caproyl-phosphatidylethanolamine
(Molecular Probes, Eugene, OR). They were formed by
exposing lipids evaporated from organic solvents to 60 mg/
mL (1.3 mM) OVA (Sigma-Aldrich) in PBS and/or to 10 mM
carboxyfluorescein (Molecular Probes), followed by extrusion
through 100-nm filters and separation from unentrapped OVA
by column filtration, as reported [13]. For this Ag concentra-
tion, we estimate about 300 molecules OVA per liposome.
Liposomes from this stock solution were diluted appropriately
for the final Ag concentration in culture. OVA concentrations
were determined with reference to co-entrapped carboxy-
fluorescein.
DC isolation
Subcutaneous LN were isolated from untreated animals or
from mice injected intravenously with 3 lg LPS 10–14 h
earlier. The LN were cut into small pieces and incubated with a
mixture of type II collagenase (Worthington) and DNase
(Sigma). The light-density cells, resuspended in 2% FCS/
EDTA/BSS, were selected by centrifugation on a Nycoprep
solution d=1.068 (Abcys), stained with anti-CD11c, CD8a and
CD205 Ab and sorted using a FACSJ Vantage and Diva software
(Becton-Dickinson). For cell culture, cells were resuspended in
RPMI 1640 medium containing 10% FCS, 2  10–5 M 2-ME,
2 mM L-glutamine and antibiotics.
Explant DC were isolated as previously described [1].
Briefly, the cartilage side was removed from mouse ears and
the skin incubated overnight with 6Ckine (CCL21)-containing
media (R&D). The cells that crawled out from the skin were
collected and corresponded to DC according to their CD11c
expression (data not shown).
In vitro Ag presentation assays
DC (2  104 or 3  103) were incubated overnight in 96-well
culture plates with either OVA peptides, free OVA or OVA
encapsulated in DNP-bearing liposomes in the presence or
absence of IgG2a anti-DNP Ab. In control experiments, free
OVAwas dialyzed against buffer before use to rule-out possible
contamination with peptides that could bind to MHC
molecules and stimulate T cells directly. Incubation of fixed
explant DC with OVA 323–339 peptide but not dialyzed or
undialyzed OVA stimulated OT-II cells, ruling out peptide
contamination (data not shown).
T cells obtained from the LN and/or spleens of OT-I or OT-II
Rag–/– mice were purified with the T cell enrichment kit from
Dynal following the manufacturer's instructions.
For CD4 and CD8 T cell proliferation assays, purified T cells
were labeled with 10 lM carboxyfluorescein diacetate succi-
nimidyl ester (CFSE, Molecular Probes) for 10 min. OT-II or
OT-I T cells (2  104) were added to DC that had been
incubated for 45 min or overnight with Ag and thenwashed. In
some experiments 2  104 OT-I and 1  104 OT-II T cells were
added to the same wells. The proliferation of OT-I and OT-II
T cells was assessed after 3 days by flow cytometry analysis, as
described [36]. The cells were washed and stained with anti-
CD4 or anti-CD8 antibodies for identification.
For CD8 Tcell cytotoxicity, 5-day DC-T cell co-cultures were
incubated for 4 h with 104 RMA (H-2b) lymphoma cells that
were 51Cr-labeled and OVA peptide SIINFEKL-pulsed (1 lM)
overnight and washed. Supernatants were harvested, and the
chromium release was measured by scintillation. The value of
RMA incubated alone was taken as 0% lysis, and the value of
target cells incubated with HCl was calculated as 100% lysis.
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In vivo Ag presentation assay
CFSE-labeled OT-I (2  106) and unlabeled OT-II (1  106 to
2  106) cells were injected intravenously into C57BL/6 mice.
Ag (3 lg) encapsulated in liposomes was injected 3 days later
either intradermally in one ear or subcutaneously in one rear
footpad. T cell proliferation was assessed 4 days later by
comparing the draining auricular or popliteal LN with the
same LN draining the non-injected side. Some mice were
injected intravenously with LPS (3 lg, Sigma) or poly I:C
(50 lg, InvivoGen) 10 h prior to Ag injection.
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